Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

PLx Pharma Winddown Corp. (PLXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
07/21/2023 8-K Quarterly results
07/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to Amended and Restated Bylaws of the Company"
05/26/2023 8-K Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, A...
Docs: "Certificate of Amendment of Certificate of Incorporation of PLx Pharma Inc",
"AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT DATED MAY 26, 2023"
05/02/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/13/2023 8-K Quarterly results
04/06/2023 SC 13G Park West Asset Management LLC reports a 4.9% stake in PLx Pharma Inc.
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A MSD Partners, L.P. reports a 2.4% stake in PLX PHARMA INC.
02/13/2023 8-K Quarterly results
01/20/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
09/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
Docs: "PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update"
05/13/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/29/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/21/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Corporation”), pursuant to the provisions of Section 109 of the Delaware General Corporation Law , hereby adopts these Amended and Restated Bylaws (the “Bylaws"
03/15/2022 8-K Investor presentation
03/11/2022 10-K Annual Report for the period ended December 31, 2021
03/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update MOMENTUM BUILDING FOR NOVEL VAZALORE LIQUID-FILLED ASPIRIN CAPSULES"
02/16/2022 SC 13G/A WHITE ROCK CAPITAL MANAGEMENT LP has filed a Schedule 13D for PLx Pharma Inc.
02/14/2022 SC 13G/A Rosalind Advisors, Inc. reports a 0% stake in PLx Pharma Inc.
02/11/2022 SC 13G/A Level One Partners, LLC reports a 14.3% stake in PLx Pharma Inc.
11/22/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/12/2021 8-K Quarterly results
Docs: "PLx Pharma Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, 2021 December 31, 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 82,554,297 $ 22,448,651 Accounts receivable, net 3,253,312 - Inventory 2,190,350 143,380 Prepaid expenses and other current assets 616,249 393,470 TOTAL CURRENT ASSETS 88,614,208 22,985,501 NON-CURRENT ASSETS Property and equipment, net 888,658 1,225,879 Right of use assets 255,121 327,161 Goodwill 2,061,022 2,061,022 Security deposit 17,036 17,036 TOTAL ASSETS $ 91,836,045 $ 26,616,599 LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 6,452,172 $ 862,568 Accrued bonuses 839,701 1,184,823 Accrued interest - 597,411 Term loan, net of discount and fees -..."
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
10/05/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/21/2021 8-K Investor presentation
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy